Soligenix Inc.

SNGX Healthcare Biotechnology

Soligenix Inc.’s revenue for fiscal 2024 (year ended December 2024) was $119,400.00, down 85.8% from fiscal 2023. In the quarter to June 2026, EPS grew 85.4% and free cash flow grew 37.8%, each against the same quarter a year earlier.

0.35 0.01 −2.78%
Market cap
$7.7M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
n/a
Altman Z
−38.90
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
3.18 2.39 1.81 2.77
Net Debt/EBITDA
4.08 2.28 2.09 4.68
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.68) (0.53) (0.23) (0.11)
Book value per Share
1.75 1.02 0.30 0.42
Free Cash Flow
(2.93) (2.75) (2.36) (1.71)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates